Tanya Dorff, MD, discusses 3 pivotal trials—PROpel, MAGNITUDE, TALAPRO-2 trial—examining the potential of combining PARP inhibitors with androgen receptor–targeted agents in patients with metastatic castration-resistant prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.